Phaseline

Targets › LASV

LASV: drug programs, companies and trials

2 programs from 2 companies in 2 trials: 2 Phase 2; Infectious disease; next expected readout Jun 2027.

Open in Phaseline: the race on LASV, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Irrua Specialist Teaching HospitalFavipiravir
RNA-directed RNA polymerase inhibitor
LASVPhase 2Lassa FeverJun 2027
International AIDS Vaccine InitiativerVSV∆G-LASV-GPC
Recombinant vesicular stomatitis virus (rVSV) expressing Lassa virus glycoprotein (GPC)
LASVPhase 2Lassa FeverJun 2027

Conditions

Lassa Fever (2)

Modalities

small molecule (2)

Companies

International AIDS Vaccine Initiative (1) Irrua Specialist Teaching Hospital (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.